Vertex Pharmaceuticals Incorporated

NASDAQ:VRTX

Biotechnology

Healthcare
$536.45 -1.40%

-$6.43 today

Market cap
$136.01B
Beta
0.31
P/E (TTM)
26.5
EPS (TTM)
$17.07
52W Low $362.50High $507.92

Volume 1.29M

Average 1.26M

VRTX Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX

Other Current Liabilities · Q3 FY2026 · quarter ended Sep 2026

Other current liabilities rises 806.2% from a year ago

Other current liabilities stood at $4B at the end of Q3 FY2026, up 806.2% from a year earlier and up 1114.5% from the prior quarter. Over 3 fiscal years it compounded at +252.9% a year.

Context

  • Other current liabilities amounted to 12.2% of total assets at the end of Q3 FY2026, up 10.4 pp from a year earlier.
  • Other current liabilities increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether other current liabilities keeps rising in the next quarterly balance sheet after a +806.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$4B+1114.5% QoQ
Last fiscal yearDec 2025
$2.75B+9.9% YoY
Year agoSep 2025
$441.5M+806.2% since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+806.2%——
1 year+9.9%——
3-year CAGR+252.9%——
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
2.75B USD
Year-over-year change
+9.9%
4-year CAGR
+259.2%

Other Current Liabilities vs competitors

How VRTX compares with its peers on the latest reported figures

  • VRTX's Sep 2026 other current liabilities of $4B is the 2nd highest of the 11 companies compared; the peer median is $157.23M.
  • Its year-over-year change of +806.2% is the 2nd highest of 11, against a peer median of +25.1%.
  • Other current liabilities amounts to 12.2% of total assets for VRTX, versus a peer median of 4.7%.
VRTX Competitors Peer median
Other Current Liabilities for VRTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BMRNBioMarin Pharmaceutical Inc.Sep 2026$946.11B +427047.9%-3.7%8.2%
VRTXVertex Pharmaceuticals IncorporatedSep 2026$4B +806.2%+252.9%12.2%
PTCTPTC Therapeutics, Inc.Jun 2026$473.08M +31.8%+17.1%14.6%
SRPTSarepta Therapeutics, Inc.Mar 2026$266.08M +59.7%+9.3%8.4%
ALNYAlnylam Pharmaceuticals, Inc.Jun 2026$258.57M +18.4%+40.8%4.7%
BBIOBridgeBio Pharma, Inc.Jun 2026$192.19M +124.7%+89.9%15.8%
CRSPCRISPR Therapeutics AGSep 2026$122.28M +65.2%+15.3%4.8%
IONSIonis Pharmaceuticals, Inc.Sep 2026$22.23M -72.8%+29.8%0.8%
RAREUltragenyx Pharmaceutical Inc.Mar 2026$17M -83.1%—1.3%
BEAMBeam Therapeutics Inc.Jun 2026$12.18M -31.2%-9.9%0.9%
NTLAIntellia Therapeutics, Inc.Mar 2026$9.32M -5.3%+1.9%1.2%
Peer median (excluding VRTX) $157.23M+25.1%+15.3%4.7%

Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents6.8B10.5B10.37B4.57B5.09B
Short-term Investments729.9M274.5M849.2M1.55B1.52B
Net Receivables1.14B1.44B1.56B1.61B2.05B
Inventory353.1M460.6M738.8M1.21B1.69B
Other Current Assets103.7M121.9M86.1M206.5M748.6M
Total Current Assets9.56B13.23B14.14B9.6B11.2B
Property, Plant & Equipment (Net)1.42B1.46B1.45B2.58B3.08B
Goodwill1B1.09B1.09B1.09B1.09B
Intangible Assets400M603.6M839.9M825.9M424.2M
Long-term Investments0112.2M2.5B5.11B5.81B
Tax Assets934.5M1.25B1.81B2.33B3.4B
Other Non-current Assets110.8M409.6M895.3M999.3M1.14B
Total Non-current Assets3.87B4.92B8.59B12.94B14.94B
Total Assets13.43B18.15B22.73B22.53B26.14B
Account Payables195M303.9M364.9M413M461.7M
Short-term Debt00092.3M82.8M
Tax Payables211.3M123.3M99.5M161.1M0
Deferred Revenue171.7M159.6M170.3M206.8M171.8M
Other Current Liabilities16.5M62.5M50.7M2.5B2.75B
Total Current Liabilities2.14B2.74B3.55B3.56B3.86B
Long-term Debt00001.85B
Deferred Tax Liabilities00001.31B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities303.3M685.8M877.7M901.8M(1.49B)
Total Non-current Liabilities1.19B1.5B1.6B2.56B3.62B
Total Liabilities3.33B4.24B5.15B6.12B7.48B
Common Stock2.5M2.6M2.6M2.6M2.5M
Retained Earnings3.2B6.52B10.14B9.61B13.56B
Accumulated OCI15.9M800K(14.3M)127.8M(15.9M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity10.1B13.91B17.58B16.41B18.67B
Total Debt967.4M899.7M808.4M1.75B3.88B
Net Debt(5.83B)(9.6B)(9.56B)(2.82B)(1.21B)

Vertex Pharmaceuticals Incorporated

NASDAQ:VRTX

Intrinsic Alpha fair value

Locked

Current Price

$536.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.